Antibiotic pipeline in peril from coronavirus and incentives system

Antimicrobial resistance (AMR) forces clinicians to look for other drugs to treat patients but the antibiotic pipeline is in dire straits. The COVID-19 pandemic is exposing how few options there are and the need for investment to be prepared for more antibiotic resistant infections to emerge, industry experts tell Axios.